IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a binding agreement with the Asian Institute of Gastroenterology (AIG) for the supply of a Proteus®ONE[1] compact proton therapy system to be located at the new Oncology Centre within AIG Hospitals’ Gachibowli campus in Hyderabad, India. The first payment has been received.
The contract includes the supply of a Proteus®ONE system and a Quality Assurance package from IBA Dosimetry. Proteus®ONE is the market leading compact proton therapy system, upgradable over time to continue to offer the latest technology to IBA users. The system will also include DynamicARC®[2] beam delivery capabilities, once this feature has received regulatory clearance.
Olivier Legrain, Chief Executive Officer of IBA, commented:
“This new contract demonstrates IBA’s strong position to meet the growing demand for proton therapy technology in India. We are pleased to enable more cancer patients to benefit from this cutting-edge technology in the region.”
Dr D Nageshwar Reddy, Chairman of AIG Hospitals added: “We are excited to be partnering with IBA to deliver the very best in cancer care. At AIG Hospitals, our unwavering commitment is to place patients at the heart of everything we do. The acquisition of IBA’s Proteus®ONE system represents a transformative step forward in our mission to provide cutting-edge, compassionate care.”
This is the first order of a Proteus®ONE system in South Asia. To date, it is only the third proton therapy center planned in the country and the second one in the private sector. AIG expects to start treating patients in early 2028.
The typical end-user price for a Proteus®ONE system with a multi-year maintenance contract ranges between EUR 35 and 45 million.
